Our results showed that MHC-II monoclonal antibody treatment successfully blocked melanoma growth in mice, leading us to hypothesize that antibodies blocking HLA class II might achieve similar tumor suppression in humans by empowering cDC2-mediated priming of CD8 T cells that recognize tumor-specific antigens. The gene discussed is CD8A; the disease is melanoma.